SCINAI IMMUNOTHERAPEUTICS LTD. (SCNI)

2.51 -6.34% (-0.17)

Over 5Y: -99.9%

2026-08-28
Style
Area Line Line with markersneeds a shorter window Steps Candlesneeds a shorter window Hollow candlesneeds a shorter window Barsneeds a shorter window

Candles need the day’s open, high and low. Those are being collected now — a company shows them once its history has been refreshed.

1 000 2 000 3 000
2021 2022 2023 2024 2025 2026

Financials Annual

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
FY21 — Operating Cash Flow: -7.4M FY21 — Free Cash Flow: -7.6M FY21 — Net Income: -8.2M FY22 — Operating Cash Flow: -7.3M FY22 — Free Cash Flow: -8.1M FY22 — Net Income: -5.8M FY23 — Operating Cash Flow: -9.4M FY23 — Free Cash Flow: -10M FY23 — Net Income: -6.5M FY24 — Revenue: 658K FY24 — Operating Cash Flow: -6.3M FY24 — Free Cash Flow: -6.3M FY24 — Net Income: 4.8M FY25 — Revenue: 1.3M FY25 — Operating Cash Flow: -6M FY25 — Free Cash Flow: -6.1M FY25 — Net Income: -8.3M -9M -6M -3M 0 3M 6M
FY21 FY22 FY23 FY24 FY25
Revenue Operating Cash Flow Free Cash Flow Net Income

Figures as at 2025-12-31, reported in USD. The newest fact in the filings is dated 2025-12-31, 242 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

0.7
SBC / sales 23.1%
OE margin -485.0%
Oper. margin -575.3%
ROIC -92.5%
Accruals -19.6%
EBITDA margin -466.9%
FCF margin -461.9%
Gross margin -202.3%
OCF margin -460.0%
Profit margin -633.6%
ROA -71.5%
ROCE -75.1%
ROE -102.5%
OCF / EBIT —

5 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
FCF yield —
Fwd P/E —
P/B —
P/C —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

2.5
RPO / sales 0.069×
RPO growth —
Segment HHI —

1 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

4.1
ND/EBITDA —
Interest cover -52.7×
Debt / Eq 0.0×
Debt payback 0.0 yr
Quick ratio 1.3×
Cash runway 0.27 yr
F-score 2.2 pts
Cash / Debt —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

4.4
Sales/sh Y/Y -31.2%
EPS Y/Y -159.8%
Shares change +189.8%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS next Y —
Sales CAGR 4Y —
Sales Q/Q —

2 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.